AC Immune (ACIU) Rating Increased to Buy at Zacks Investment Research

AC Immune (NASDAQ:ACIU) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Monday, August 6th. The brokerage presently has a $10.00 price target on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 7.64% from the company’s previous close.

According to Zacks, “AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. “

ACIU has been the subject of several other reports. ValuEngine raised AC Immune from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Credit Suisse Group set a $14.00 target price on AC Immune and gave the company a “hold” rating in a report on Thursday, May 3rd. Finally, BidaskClub upgraded AC Immune from a “hold” rating to a “buy” rating in a report on Monday, June 18th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $14.00.

NASDAQ ACIU traded down $0.30 on Monday, reaching $9.29. 111,135 shares of the stock traded hands, compared to its average volume of 85,156. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.65 and a current ratio of 9.65. The firm has a market cap of $563.13 million, a P/E ratio of -30.97 and a beta of 2.24. AC Immune has a 12 month low of $6.94 and a 12 month high of $17.40.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings data on Wednesday, August 8th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.04. The business had revenue of $2.03 million during the quarter, compared to analyst estimates of $1.92 million. AC Immune had a negative return on equity of 25.44% and a negative net margin of 133.00%. research analysts predict that AC Immune will post -0.93 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in AC Immune stock. Renaissance Technologies LLC acquired a new position in shares of AC Immune SA (NASDAQ:ACIU) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 11,200 shares of the company’s stock, valued at approximately $143,000. Institutional investors and hedge funds own 16.69% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Further Reading: Stop Order Uses For Individual Investors

Get a free copy of the Zacks research report on AC Immune (ACIU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply